Aligos Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Aligos Therapeutics

03/08/2023 22:52

* Aligos Therapeutics Inc  ALGS.OQ  reported a quarterly
adjusted
loss of 43 cents​​ per share for the quarter ended in June. The
mean expectation of three analysts for the quarter was for a
loss of 49 cents per share.
    * Revenue rose 86.5% to $6.89 million from a year ago;
analysts
expected zero. 
    * Aligos Therapeutics Inc's reported EPS for the quarter was
a
loss of 43 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Aligos Therapeutics Inc shares had fallen by 7.5% this
quarter and lost 5.7% so far this year.
    * The company reported a quarterly loss of $18.79 million.
    * Wall Street's median 12-month price target for Aligos
Therapeutics Inc is $3.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 3 at 09:51 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.49          -0.43          Beat
 Mar. 31 2023      -0.48          -0.53          Missed
 Dec. 31 2022      -0.47          -0.51          Missed
 Sep. 30 2022      -0.58          -0.44          Beat